Our findings demonstrate that tofacitinib treatment early during infection ameliorates intestinal inflammation driven by human mucosal pathogen C. jejuni in both IL-10 KO mice and in humanized mice with intact IL-10 signaling. This evidence concerns the gene IL10 and infection.